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Lipocalin-like Prostaglandin D Synthase (L-PGDS)
Concentration in Aqueous Humour in Patients With
Open-angle Glaucoma
Gregor Bauer, MD,*w Hanspeter E. Killer, MD,*z Andreas Forrer, MD,* Andreas R. Huber, MD,y
and Gregor P. Jaggi, MD*w
Purpose: To report on the concentration of lipocalin-like prosta-
glandin D synthase (L-PGDS) in the aqueous humour (AH) in
patients with open-angle glaucoma (OAG).
Patients and Methods: Prospective assessment in 20 patients (13
female, 7 male, mean age 74±10.6 y) who underwent surgery for
OAG. AH was sampled and analyzed for L-PGDS concentration.
AH from 26 patients (11 female, 15 male, 72.4±14.4 y) without
glaucoma who underwent cataract surgery, served as control
subjects.
Results: The L-PGDS concentration in the AH sampled from the
anterior chamber in the OAG group (5.9±2.4mg/L) was sig-
niﬁcantly (P<0.001) higher than in the control group
(3.3±1.3mg/L). There were no signiﬁcant diﬀerences between the
concentrations of L-PGDS between the left and the right eye or
between genders.
Conclusions: L-PGDS concentration in the AH of patients with
OAG was signiﬁcantly elevated compared with its concentration in
the AH of nonglaucomatous eyes. As L-PGDS is a biologically
pluripotent protein, its possible role in glaucoma warrants further
examination.
Key Words: lipocalin-like prostaglandin D synthase, b-trace, open-
angle glaucoma, aqueous humour
(J Glaucoma 2012;00:000–000)
The pathology of open-angle glaucoma (OAG) is stillpoorly understood. Elevated intraocular pressure (IOP)
is the best established risk factor for the development and
progression of OAG,1,2 but there remain patients who
develop typical glaucomatous ﬁeld and disc changes despite
IOPs consistently in the range generally considered normal.
In some of these patients, who are said to have “normal-
tension glaucoma” (NTG) or “low-tension glaucoma,”3
vascular dysregulation is thought to be a risk factor for the
development of disc cupping and visual ﬁeld loss.4 In oth-
ers, recent research regarding the pathophysiology of the
disorder has focused on the anatomy of the subarachnoid
space (SAS) surrounding the orbital portion of the optic
nerve and of the content of the cerebrospinal ﬂuid (CSF) in
this space.5 In addition the eﬀect of the translaminar
pressure gradient on the lamina cribrosa may be impor-
tant.6,7 Additional research in this area has focused on
humoral abnormalities in patients with OAG. A number of
molecules are currently under investigation, such as endo-
thelin-1,8 vascular endothelial growth factor,9 tumor
necrosis factor-alpha,10 matrix metalloproteinases, and
their inhibitors.11
Lipocalin-like prostaglandin D synthase (L-PGDS,
also called b-trace protein) is a mainly brain-derived protein
with a molecular mass of 28 kD. It is the most abundant
protein in CSF.12,13 It has been reported to induce neuronal
cell protection and neuronal cell loss, depending on the
receptor pathway it signals to target cells.14–16 In the rat
eye, L-PGDS was found in the retinal pigment epithelium
and in the interphotoreceptor matrix.17,18 In addition,
messenger ribonucleic acid for prostaglandin D2 has been
described in the retina.19 The retinal pigment epithelium is
suggested to be the predominant site of production for
prostaglandin D2, which is synthesized by L-PGDS, in the
eye.18 Astrocytes (in vitro) are another source of L-PGDS
production.20 Recently it has been shown that L-PGDS
inhibits astrocyte proliferation and adenosine triphosphate
production in vitro.21 L-PGDS has also been shown to be
upregulated in the local CSF in patients with papilledema
from a variety of causes.22 In addition, a study of patients
with NTG demonstrated a L-PGDS concentration gradient
between the CSF obtained from the SAS surrounding the
optic nerve during optic nerve sheath fenestration and the
lumbar CSF obtained by lumbar puncture.23
L-PGDS is a pluripotent protein in the central nervous
system and in some structures of the eyeball. In order to
evaluate its potential role in OAG we measured its con-
centration in the anterior chamber of glaucomatous eyes
and in eyes without glaucoma. To the best of our knowl-
edge this is the ﬁrst quantitative analysis of L-PGDS con-
centration in the aqueous humour (AH) of human OAG
patients.
PATIENTS AND METHODS
Twenty patients (overall mean age, 73.8±10.6 y)—13
women (mean age, 78.0±7.7 y) and 7 men (mean age,
65.9±11.2 y)—with a diagnosis of OAG based on optic
disc appearance and visual ﬁeld defects were recruited for a
prospective study. Twenty-six patients (mean age, 72.4±
14.4 y)—11 women (mean age, 77.3±9.2 y) and 15 men
(mean age, 68.7±16.6 y)—with normal appearance of their
optic discs and without pseudoexfoliation (PEX) or obvi-
ous anterior chamber angle abnormalities and without
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known visual ﬁeld defects undergoing cataract surgery,
were enrolled prospectively and served as controls. All
patients and controls underwent complete ophthalmo-
logical examination. None of the OAG patients had
undergone previous trabeculectomy and none had under-
gone cataract surgery within the last 6 months.
All of the OAG patients had been treated with IOP-
lowering topical medication for at least several weeks at the
time of surgery and sampling of AH, and 3 also had been
taking acetazolamide for several weeks. Sixteen of the 20
patients (80%) underwent trabeculectomy because of insuﬃ-
cient IOP lowering or adverse eﬀects of the topical and/or
systemic treatment. Of these 16 patients, 12 (mean age,
72.8±10.5 y) underwent trabeculectomy only, whereas 4
(69.8±10.8 y) underwent combined trabeculectomy and cat-
aract surgery. The remaining 4 OAG patients (80.8±9.9y)
had IOPs that were deemed to be in the appropriate range,
were tolerating their topical medication well, and underwent
only cataract surgery. Mean IOP in the OAG patients was
22.0±6.0mm Hg, ranging from 13 to 34mm Hg (median,
21.5mm Hg). Mean IOP in the control group was
14.4±3.1mm Hg, ranging from 10 to 19mm Hg (median,
14.5mm Hg) (Table 1).
AH (0.1 to 0.2mL) was sampled from the anterior
chamber at the beginning of the operation using a 26-G
needle (Terumo, Belgium) and a sterile syringe (Omniﬁx U-
100 Insulin, Braun, Germany). Special care was taken not
to apply ﬂuids before sampling AH so as not to induce
diluting eﬀects. L-PGDS concentration was measured using
a fully automated, standard BNII nephelometer (Dade
Behring, Marburg, Germany) and commercial reagents.
Before determination of L-PGDS, 7-point calibration
curves were generated. If necessary, samples were diluted so
that the results would fall in the linear range. Daily controls
with appropriate standards are obtained to guarantee sta-
bility of the system. The minimal quantity of ﬂuid required
for reliable nephelometry is 0.02mL. At least 3 measure-
ments were performed from each sample and mean value
was calculated. Three diﬀerent surgeons from the same
department were involved; all measurements were made in
the same laboratory.
Statistical analyses were conducted with SPSS stat-
istical analysis software (SPSS Inc., Chicago, IL). An inde-
pendent 2-tailed t test and the Spearmans nonparametric
correlation coeﬃcient r were used, unequal variances were
assumed.
This study was designed and performed according to
the tenets of the Declaration of Helsinki and was approved
by the local ethics committee. Written informed consent
was provided by all patients and control subjects.
RESULTS
The subjects in the OAG and control groups did not
diﬀer signiﬁcantly in age for women (P=0.84) or men
(P=0.64). In the 20 OAG patients, the mean concen-
tration of L-PGDS in the AH was 5.9±2.4mg/L, with no
diﬀerence between right and left eyes [P=0.79; right eyes
(n=12): 5.8±2.8mg/L; left eyes (n=8): 6.1±1.7mg/L],
or between women and men [P=0.48; women (n=13):
5.7±2.7mg/L; men (n=7): 6.4±1.8mg/L). In the 12
OAG patients who underwent trabeculectomy, mean
L-PGDS concentration in the AH was 6.2±2.6mg/L,
whereas in the 4 patients who underwent combined trabe-
culectomy and cataract surgery, mean L-PGDS was
5.8±2.9mg/L. In the 4 OAG patients who underwent only
cataract surgery, mean L-PGDS concentration in the AH
was 5.4±1.8mg/L. In the 26 control subjects, the mean
concentration of L-PGDS in AH was 3.3±1.3mg/L. As in
the case of the OAG patients, there was no diﬀerence in
L-PGDS concentration between right and left eyes
[P=0.87; right eyes (n=16): 3.3±1.5mg/L; left eyes
(n=10): 3.2±1.0mg/L] or between women and men
[P=0.93; women (n=11): 3.3±1.5mg/L; men (n=15):
3.3±1.2mg/L]; however, the mean L-PGDS concentration
in the AH obtained from the OAG patients was sig-
niﬁcantly higher than the concentration from the controls
(P<0.001; Fig. 1).
In the OAG group, there were no signiﬁcant diﬀer-
ences in concentration of L-PGDS in AH among patients
who underwent trabeculectomy, combined trabeculectomy,
and cataract surgery, or just cataract surgery (P>0.53),
nor were there signiﬁcant diﬀerences between the OAG
patients with PEX and without PEX (P=0.13; mean for
OAG with PEX=7.1±3.1mg/L; mean for OAG without
PEX=5.1±1.5mg/L). Mean L-PGDS concentration in
the AH from 16 OAG patients treated with topical pros-
taglandin analogs was 5.8±2.0mg/L, which was not sig-
niﬁcantly (P=0.75) diﬀerent from the 4 OAG patients who
were not being treated with topical prostaglandin analog
therapy (6.5±4.1mg/L).
Mean IOP in the OAG group (22.0±6.0mm Hg) was
signiﬁcantly (P=0.003) higher than in the control group
(14.4±3.1mm Hg). The IOP diﬀerences between women
and men were not signiﬁcant in the OAG group (P=0.40)
or in the control group (P=0.64), nor were there sig-
niﬁcant diﬀerences in IOP between right and left eyes in
either the OAG group (P=0.75) or the control group
(P=0.81). The preoperative IOP in the 4 OAG patients
who underwent cataract surgery was signiﬁcantly lower
than the preoperative IOP in the 12 OAG patients who
underwent trabeculectomy (P=0.002) but did not diﬀer
signiﬁcantly from that of the 4 OAG patients who under-
went combined trabeculectomy and cataract surgery
(P=0.16). There was no signiﬁcant diﬀerence (P=0.99) in
IOP between the 16 OAG patients who were being treated
with prostaglandin analogs and the 4 OAG patients who
were not being treated with any of these drugs. There was
also no signiﬁcant diﬀerence in preoperative IOP between
OAG patients with and without PEX (P=0.29; mean for
OAG with PEX=23.8±6.3mm Hg; mean for OAG
without PEX=20.8±5.8mm Hg).
There was no signiﬁcant correlation (Spearman cor-
relation coeﬃcient) between L-PGDS concentration and age
(P=0.63, r=0.074) or systemic dosage of acetazolamide
(P=0.098, r=0.247); however, if analyzing all patients
and controls together in 1 group, L-PGDS concentration was
signiﬁcantly correlated with preoperative IOP (P=0.006,
r=0.40), whereas when OAG patients and controls were
analyzed separately, there was no signiﬁcant correlation
between L-PGDS concentration and IOP (OAG patients:
P=0.204, r=0.297; controls: P=0.88, r=0.031; Fig. 2).
Subgroup analysis of the 4 OAG patients who
underwent cataract surgery only together with the control
group did not reveal a signiﬁcant correlation between
L-PGDS concentration and IOP (P=0.678, r=0.79).
These 4 OAG patients showed a signiﬁcantly lower IOP
than the rest of the OAG group (P=0.002), as did the
control group (P=0.003). Comparing only these 4 OAG
patients with the control group and assuming unequal
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variances, there was no statistically signiﬁcant diﬀerence for
L-PGDS concentration (P=0.096), whereas there was a
signiﬁcant diﬀerence in IOP (controls mean: 14.4±3.1mm
Hg, 4 purely cataract surgery OAG patients 17.0±1.4mm
Hg; P=0.022). Assuming equal variances and comparing
the same 2 subgroups the unpaired 2-tailed t test showed an
insigniﬁcant diﬀerence for IOP (P=0.116) but a signiﬁcant
diﬀerence for L-PGDS concentration (P=0.007).
DISCUSSION
In this study of the substance L-PGDS in the AH of
patients with OAG compared with control subjects without
OAG, we found the concentration of L-PGDS in the AH of
the OAG patients (mean 5.9±2.4mg/L) to be signiﬁcantly
higher than in the controls (3.3±1.3mg/L). The concen-
tration of L-PGDS in the serum of normal human adults is
very low (<0.55mg/L),24 whereas reference values for
L-PGDS in normal human CSF are at least 30 times higher
(15.3±2.7mg/L).25 The range of L-PGDS concentration in
AH found in the OAG and in the control group is between
the normal values for serum and CSF. A local L-PGDS
production in structures of the eye, has already been dem-
onstrated in mice and rats.19 Additional proof for local
production of L-PGDS in the eye was indicated in a study
that investigated the concentration of L-PGDS in the sub-
retinal ﬂuid in retinal detachment. The authors of this study
found that the L-PGDS concentration correlated with the
duration of the detachment,26 being high in patients with
a short history of symptoms and low in longstanding
detachments.
The present study describes an interesting and sig-
niﬁcant correlation between the L-PGDS concentrations in
the AH and the preoperatively IOP if analyzing all patients
and controls at once; speciﬁcally, the higher the pre-
operatively measured IOP, the higher the L-PGDS con-
centration in the AH. Even if a selection bias could lead to
this correlation (because mainly patients with so far insuf-
ﬁcient IOP lowering treatment were indicated for inter-
ventional therapy of OAG), it seems possible that there
is IOP sensitive increase in L-PGDS expression of the
intraocular tissue in patients with OAG. However, if sub-
grouping and analyzing OAG and control patients sepa-
rately we were not able to ﬁnd a signiﬁcant correlation
between L-PGDS concentration and IOP. Because of the
small number of samples, which is probably the main lim-
itation of this study, further subgroup analysis seem not to
yield reliable results, which can be seen in the Results sec-
tion (ie, analysis of the small subgroup of the 4 OAG
patients who underwent only cataract surgery and who had
lower IOP values than the rest of the OAG group).
Therefore, the question of mechanosensitivity needs to be
addressed in a larger cohort of OAG patients and in
patients with NTG.
The possible role of L-PGDS in the pathophysiology of
glaucoma needs to be addressed and concerning its possible
pathophysiological mechanisms. Several mechanisms may
be involved. L-PGDS is a prostaglandin synthase with a
pluripotent activity. In particular, it has apoptosis-inducing
properties in neuronal tissue.13,15,16,25 In addition, immu-
noﬂuorescence studies in nonhuman primate brains has
demonstrated a close spatial relationship of L-PGDS to
astrocytes and oligodendrocytes.27 These cell types are mainly
located in white matter tissue, such as the optic nerve. The
hallmark of glaucomatous optic neuropathy is excavation of
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FIGURE 2. Scatter plot of concentration of lipocaline-like pros-
taglandin D synthase (L-PGDS; mg/L) in the aqueous humour
(AH) and preoperatively intraocular pressure (IOP; mm Hg)
measured by goldmann applanation tonometry, of open-angle
glaucoma patients with prostaglandin analogous topical medi-
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medication (OAG), and nonglaucomatous cataract patients
serving as controls (Co).
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the optic disc due to the progressive loss of nerve ﬁbers. In
contrast to the normal disc, the lamina cribrosa, which builds
the barrier between the SAS and the vitreous cavity, in a
patient with glaucoma can possibly loose its tightness as the
space that might be left empty by the degenerated nerve ﬁbers
could function as a “canal.” Therefore a connection between
the SAS and the vitreous cavity could be postulated. Through
this route, L-PGDS from the CSF might enter the eyeball and
the anterior chamber.
In order to elucidate the relation between elevated
L-PGDS levels in AH and IOP, further studies measuring
L-PGDS concentrations in AH of patients with NTG and
patients with ocular hypertension are needed.
This study does not address the question whether the
elevated L-PGDS concentration in the AH of OAG patients
is part of the pathomechanism of glaucomatous optic disc
changes or is an epiphenomena, the consequence of the
pathological changes in the metabolism of glaucomatous
eyes in general; however, in light of the recently reported
eﬀect of L-PGDS on astrocytes and their adenosine tri-
phosphate production in vitro21 and the previously
reported eﬀects on other neuronal cells,28,29 it seems fea-
sible that L-PGDS concentration could play an important
role in modulating apoptosis or survival of neuronal cells in
glaucomatous optic neuropathy.
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